Explore the Agenda

Day One

Wednesday, August 5

Day Two

Thursday, August 6

8:00 am Check-in, Coffee & Networking

8:45 am Chair’s Opening Remarks

Executive Vice President, General Counsel, Parabilis Medicines

Deploying Responsible AI to Amplify Legal Capacity & Strengthen Enterprise Oversight

9:00 am Accelerating FDA Submissions Through AI-Assisted Module Drafting to Reduce Risk & Enhance Regulatory Efficiency

General Counsel & Corporate Secretary , Enveda Therapeutics, Inc.
  • Shortening submission timelines and expanding legal and regulatory capacity by embedding AI into FDA module drafting for a live Phase 2 asset
  • Mitigating hallucination, confidentiality, and trade-secret exposure through structured guardrails, validation workflows, and disciplined human oversight
  • Demonstrating measurable ROI through a real-world implementation with an external AI partner while preserving defensibility and data integrity

9:30 am Generative AI for Maintaining Contract Compliance & Negotiation Power in BioPharma

Senior Account Manager, CobbleStone Software
  • Increase legal team capacity without adding headcount by automating contract drafting, review, and information retrieval through generative AI
  • Improve compliance and governance by standardizing contract language and embedding approved playbooks directly into contracting workflows
  • Create a centralized contract intelligence hub that enables faster decision-making, stronger negotiations, and greater visibility across the contract lifecycle

9:40 am Panel Discussion: Establishing AI Governance Frameworks to Enable Safe, Scalable Adoption

Chief Legal Officer & Corporate Secretary, Olema Oncology
Chief Legal Officer, Head of Quality & Corporate Secretary, Boundless Bio
Executive Vice President, General Counsel, Parabilis Medicines
Chief Legal Officer, Gameto
Assistant General Counsel, Beckman Coulter Inc.
  • Reduce legal and ethical exposure through validated guardrails and approval processes
  • Empower teams to adopt AI confidently without breaching policy or regulatory expectations
  • Prevent misuse with monitoring, access controls, and cross-functional oversight, while accounting for emerging differences between federal guidance and state‑level AI regulations

10:25 am Morning Break & Networking

Optimizing IP & Trade Secrets to Strengthen Competitive Positioning, Deal Leverage & LongTerm Defensibility

10:55 am Panel Discussion: Ensuring Cross-Functional Alignment to Safeguard IP Defensibility & Preserve Enterprise Value

General Counsel & Corporate Secretary , Enveda Therapeutics, Inc.
Head of Intellectual Property, Crescent Biopharma
Principal & Fractional CSO, Gene Editing Frontiers
SVP, Legal & Alliance Management (Head of IP), Mammoth Biosciences
Partner, Patents & Innovations, Wilson Sonsini Goodrich & Rosati
Executive Director, Intellectual Property, Umoja Biopharma
  • Strengthening collaboration between scientific, regulatory and legal teams to support robust patent scope and resilient trade-secret protection
  • Coordinating disclosure timing, data generation, and regulatory positioning to strengthen valuation, diligence readiness, and lifecycle strategy
  • Reducing risks in downstream enforcement, inventorship, and documentation risk in an increasingly AI-enabled R&D environment

11:40 am Fireside Chat: Aligning IP Strategy to Protect Assets and Strengthen Deal Leverage

Vice President Head of Intellectual Property, Generate Biomedicines, Inc
SVP, Legal & Alliance Management (Head of IP), Mammoth Biosciences
  • Build a deal-ready IP position by aligning exclusivity, data generation, and disclosure timing with partner expectations
  • Avoid deal blockers by addressing ownership, platform boundaries, and other IP issues that commonly surface during negotiations
  • Strengthen leverage with a clear IP narrative that distinguishes asset IP from platform IP and supports confident decision-making

12:10 pm Panel Discussion: Read Between the Filings: The Story Your Data Won’t Say Out Loud

Sr. Director of Solutions, Park IP
Head of Global Sales, Park IP
  • Spot the coverage gaps forming in your own portfolio, using filing data showing a 56% drop in average jurisdictions per chem/bio PCT application in just two years (4.3 in 2023 to 1.9 in 2025)
  • Identify which jurisdictions carry the most risk today, as filing rules shift fastest and competitive filings surge in the same markets biopharma companies are exiting
  • Leave with three concrete moves to rebalance filing strategy before narrower coverage becomes a liability in FTO, deal, or litigation decisions

12:40 pm Networking Lunch

Structuring Strategic Collaborations & Navigating Geopolitical Complexity to Maintain Operational Continuity

1:40 pm Fireside Chat: Structuring Biotech Collaborations for Value, Control and Longevity

General Counsel & Corporate Secretary, Arbor Biotechnologies, Inc.
  • Current negotiation trends in licensing and collaboration deals with big pharma and peer biotechs in competitive global markets
  • Strategies for protecting platform IP and downstream inventions in collaborations
  • Governance frameworks supporting long-term alliances to maximize control and maintain strategic focus

2:10 pm Panel Discussion: Anticipating Geopolitical & Trade Policy Shifts to Preserve Cross-Border Operational Continuity

General Counsel, Eyexora
Group General Counsel, Telix Pharmaceuticals
  • Reduce enterprise disruption by tracking geopolitical shifts affecting trade access, regulatory cooperation, and BIOSECURE-driven supply-chain exposure
  • Protect international growth by aligning global footprint and manufacturing strategy with export controls, industrial policy, and supply-continuity risks
  • Strengthen board readiness with scenarios that maintain stability amid tariff escalation and policy shocks

2:40 pm Afternoon Networking Break

3:09 pm Elevating GC Leadership to Strengthen Cross-Functional Alignment & Executive Impact

3:10 pm Fireside Chat: Influencing the Board During Volatility to Strengthen Strategic Judgment

Chief Legal Officer, Caribou Biosciences, Inc.
  • Deliver decision-ready counsel during regulatory, pricing, or capital-market uncertainty
  • Shape board-level debate by framing risk trade-offs with clarity and commercial awareness
  • Build long-term credibility through disciplined, forward-looking governance leadership

3:40 pm Roundtable Discussions: Embedding Legal Leadership to Accelerate Cross-Functional Execution

Formerly General Counsel & Head of Compliance, Corstasis Therapeutics
Chief Legal Officer & Corporate Secretary, Olema Oncology
Executive Vice President, General Counsel, Parabilis Medicines

4:25 pm Fireside Chat: Developing the Next Generation of GC Leadership to Strengthen Succession & Enterprise Resilience

General Counsel & Corporate Secretary, Arbor Biotechnologies, Inc.
Chief Legal Officer, Indivior Plc.
Executive Vice President, General Counsel, Parabilis Medicines
  • Build internal talent pipelines by intentionally developing senior counsel for broader enterprise leadership
  • Equip high-performing in-house lawyers with the judgment, cross-functional fluency, and board exposure required for GC readiness
  • Strengthen organizational stability through deliberate succession planning and leadership mentoring

4:55 pm Chair’s Closing Remarks

Executive Vice President, General Counsel, Parabilis Medicines

5:00 pm End of the 7th In-House Impact: Biopharma Summit